Navigation Links
NeuroPhage Extends Series B to $21.4M
Date:3/8/2012

CAMBRIDGE, Mass., March 8, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, announced today that it has secured $9.0 million in Series B-1. Dr. Michael Grundman, an Alzheimer's disease clinical expert, President and CEO of the consulting firm Global R& D Partners, LLC, has joined the NeuroPhage team to lead the clinical development of NPT002. The round was completed by existing investors, including Merieux Developpement, Shire, and private investors. The Series B-1 financing brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. The terms of the financing were not disclosed. 

Dr. Richard Fisher, NeuroPhage's CSO said: "The continued support of all of our investors enables us to fully exploit our recent breakthrough around the mechanism of action of NPT002."

About NeuroPhage

NeuroPhage is a biotechnology company focusing on a unique approach for treating diseases involving protein aggregation. NeuroPhage was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
2. Forensic research extends detection of cyanide poisoning
3. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
4. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
5. PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
6. PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation
7. U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029
8. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
9. ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization
10. Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China
11. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):